Table 4

Logistic multivariate regression to detect independent associations between anti-FOXE3p53-62 Ab levels and clinical and laboratory parameters (continuous and dichotomized) in 75 ACA+ patients

Variable

B coefficient

Exp (B)

P-valuea

95% CI


Gender

-0.065

1.067

0.956

0.104, 0.914

Age at diagnosis

-0.022

0.978

0.465

0.922, 1.038

Disease duration

0.039

1.040

0.661

0.943, 1.096

mRss

-0.06

0.942

0.277

0.846, 1.049

ESR

0.004

1.004

0.847

0.962, 1.049

CRP

-0.052

0.949

0.749

0.689, 1.307

ANA titer

0.000

1.000

0.550

0.999, 1.002

Anti-Ap1-17 IgG

0.00

1.000

0.678

0.999, 1.001

Anti-Ap17-30 IgG

0.108

1.114

0.035

1.007, 1.231

Disease severity score

0.138

1.148

0.315

0.977, 1.501

Disease activity index

-0.711

0.491

0.035

0.254, 0.950


aA P-value >0.05 was not considered statistically significant. ACA, anti-centromere-associated protein antibodies; ANA, anti-nuclear antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; mRss, modified Rodnan skin score.

Perosa et al. Arthritis Research & Therapy 2013 15:R72   doi:10.1186/ar4249

Open Data